Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A02124 | 34497708 | Ther Adv Endocrinol Metab | Therapeutic approaches for non-alcoholic steatohepatitis. | 2021 | Details |
| A02130 | 34496054 | Hepatology | Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. | 2021 | Details |
| A02133 | 34494384 | Hepatol Commun | Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis. | 2021 | Details |
| A02135 | 34493137 | Expert Rev Gastroenterol Hepatol | Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. | 2021 | Details |
| A02139 | 34490745 | Pediatr Obes | Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children. | 2021 | Details |
| A02143 | 34489307 | Gut | Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. | 2021 | Details |
| A02146 | 34486981 | Endocr Connect | Nonalcoholic steatohepatitis: global impact and clinical consequences. | 2021 | Details |
| A02149 | 34486129 | Alcohol Clin Exp Res | Multiparametric magnetic resonance imaging/magnetic resonance elastography assesses progression and regression of steatosis, inflammation, and fibrosis in alcohol-associated liver disease. | 2021 | Details |
| A02158 | 34482352 | AIDS | Single nucleotide polymorphisms in PNPLA3, ADAR-1 and IFIH1 are associated with advanced liver fibrosis in patients co-infected with HIV-1//hepatitis C virus. | 2021 | Details |
| A02162 | 34479517 | BMC Pediatr | Higher BMI predicts liver fibrosis among obese children and adolescents with NAFLD - an interventional pilot study. | 2021 | Details |
| A02164 | 34478753 | Metabolism | Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk. | 2021 | Details |
| A02169 | 34476007 | J Cancer | Research progress, challenges and perspectives on PNPLA3 and its variants in Liver Diseases. | 2021 | Details |
| A02171 | 34475864 | Front Microbiol | Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children. | 2021 | Details |
| A02175 | 34474517 | Endocrinol Metab (Seoul) | Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts. | 2021 | Details |
| A02179 | 34472683 | Hepatol Res | MAFLD: Renovation of clinical practice and disease awareness of fatty liver. | 2021 | Details |
| A02183 | 34470931 | Nihon Yakurigaku Zasshi | [Development of liver organoids from NASH model mice and their application to drug discovery]. | 2021 | Details |
| A02185 | 34469884 | Dig Dis | Transaminase Concentrations Cannot Separate Non-Alcoholic Fatty Liver and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Irrespective of Histological Algorithm. | 2021 | Details |
| A02187 | 34469404 | J Clin Gastroenterol | Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease: A Review of the Literature With Recommendations. | 2021 | Details |
| A02190 | 34466796 | JHEP Rep | Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis. | 2021 | Details |
| A02193 | 34466067 | Saudi J Biol Sci | Prevalence and predictors of non-alcoholic fatty liver disease in tertiary care hospital of Taif, Saudi Arabia: A retrospective study. | 2021 | Details |
| A02208 | 34459959 | Eur J Pediatr | Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial. | 2021 | Details |
| A02211 | 34459096 | Liver Int | Changing clinical management of NAFLD in Asia. | 2021 | Details |
| A02214 | 34456873 | Front Endocrinol (Lausanne) | Purinergic Signaling in Liver Pathophysiology. | 2021 | Details |
| A02215 | 34456869 | Front Endocrinol (Lausanne) | Free Triiodothyronine Is Associated With Hepatic Steatosis and Liver Stiffness in Euthyroid Chinese Adults With Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A02219 | 34455284 | Curr Opin Pharmacol | An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities. | 2021 | Details |
| A02221 | 34454994 | J Hepatol | Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. | 2021 | Details |
| A02224 | 34453963 | J Hepatol | Epidemiology and risk-stratification of NAFLD-associated HCC. | 2021 | Details |
| A02228 | 34453359 | Hepatology | Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. | 2021 | Details |
| A02229 | 34453237 | J Med Ultrason (2001) | Quantitative assessment of fatty liver using ultrasound attenuation imaging. | 2021 | Details |
| A02230 | 34453120 | Lab Invest | Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH. | 2021 | Details |
| A02233 | 34450307 | Pharmacol Res | Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis. | 2021 | Details |
| A02235 | 34450119 | Exp Cell Res | miR-23b Ameliorates nonalcoholic steatohepatitis by targeting Acyl-CoA thioesterases 4. | 2021 | Details |
| A02242 | 34448598 | Metab Syndr Relat Disord | Non-Alcoholic Steatohepatitis Severity Associates with FGF21 Level and Kidney Glucose Uptake. | 2021 | Details |
| A02243 | 34448436 | J Histochem Cytochem | Independent of Calorie Intake, Short-term Alternate-day Fasting Alleviates NASH, With Modulation of Markers of Lipogenesis, Autophagy, Apoptosis, and Inflammation in Rats. | 2021 | Details |
| A02247 | 34447378 | Front Immunol | Crosstalk Between Plasma Cytokines, Inflammation, and Liver Damage as a New Strategy to Monitoring NAFLD Progression. | 2021 | Details |
| A02251 | 34446271 | Clin Ther | Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A02254 | 34445644 | Int J Mol Sci | Resveratrol and Quercetin as Regulators of Inflammatory and Purinergic Receptors to Attenuate Liver Damage Associated to Metabolic Syndrome. | 2021 | Details |
| A02261 | 34444807 | Nutrients | Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut-Liver Axis. | 2021 | Details |
| A02268 | 34441028 | Medicina (Kaunas) | Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions. | 2021 | Details |
| A02275 | 34440507 | Life (Basel) | Association of Nonalcoholic Hepatic Fibrosis with Body Composition in Female and Male Psoriasis Patients. | 2021 | Details |
| A02279 | 34439491 | Antioxidants (Basel) | TRPM2 Non-Selective Cation Channels in Liver Injury Mediated by Reactive Oxygen Species. | 2021 | Details |
| A02282 | 34439154 | Cancers (Basel) | A Novel Orthotopic Liver Cancer Model for Creating a Human-like Tumor Microenvironment. | 2021 | Details |
| A02287 | 34435378 | Aliment Pharmacol Ther | Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. | 2021 | Details |
| A02289 | 34435032 | ERJ Open Res | 1-year outcomes for lung transplantation recipients with non-alcoholic fatty liver disease. | 2021 | Details |
| A02292 | 34434058 | Int J Gen Med | Elevated Serum Cyclophilin D Level is Associated with Nonalcoholic Fatty Liver Disease and Higher Fibrosis Scores in Patients with Diabetes Mellitus. | 2021 | Details |
| A02297 | 34432804 | PLoS One | Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study. | 2021 | Details |
| A02298 | 34432123 | Eur Radiol | Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis. | 2021 | Details |
| A02300 | 34431493 | J Clin Endocrinol Metab | LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia. | 2022 | Details |
| A02305 | 34427662 | Clin Sci (Lond) | Exposure to cigarette smoke precipitates simple hepatosteatosis to NASH in high-fat diet fed mice by inducing oxidative stress. | 2021 | Details |
| A02314 | 34422459 | Cureus | Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A02317 | 34422075 | Evid Based Complement Alternat Med | Antifibrotic Effects of Kangxian Ruangan Capsule on Rats with Nonalcoholic Fatty Liver Fibrosis and Hepatic Stellate Cells through Regulation of TGF-β and TLR4 Signaling Pathways. | 2021 | Details |
| A02320 | 34420934 | Gut Liver | Multidimensional Biomarker Analysis Including Mitochondrial Stress Indicators for Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A02325 | 34418914 | Endocrinol Metab (Seoul) | High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study. | 2021 | Details |
| A02330 | 34416040 | Aliment Pharmacol Ther | Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. | 2021 | Details |
| A02334 | 34414507 | Virchows Arch | Hepatocellular carcinoma in primary sclerosing cholangitis and primary biliary cholangitis: a clinical and pathological study in an uncommon but emerging setting. | 2021 | Details |
| A02341 | 34411400 | Liver Int | Bile acid dysmetabolism in the gut-microbiota-liver axis under hepatitis C virus infection. | 2021 | Details |
| A02343 | 34410573 | Dig Dis Sci | A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A02346 | 34408183 | Sci Rep | Key features of the environment promoting liver cancer in the absence of cirrhosis. | 2021 | Details |
| A02349 | 34406410 | J Clin Endocrinol Metab | The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. | 2022 | Details |
| A02358 | 34404276 | Crit Rev Food Sci Nutr | Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. | 2021 | Details |
| A02363 | 34402473 | Eur J Gastroenterol Hepatol | Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression. | 2021 | Details |
| A02366 | 34401141 | Ann Med Surg (Lond) | Prevalence of fatty liver disease and its associated factors among Jordanian patients with type 2 diabetes mellitus: A cross-sectional study. | 2021 | Details |
| A02369 | 34400217 | Metabolism | Diabetes and metabolic dysfunction-associated fatty liver disease. | 2021 | Details |
| A02370 | 34400208 | J Pediatr | Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin. | 2021 | Details |
| A02372 | 34400007 | Clin Ther | Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications. | 2021 | Details |
| A02373 | 34399601 | Int J Immunopathol Pharmacol | Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice. | 2022 | Details |
| A02376 | 34398492 | Aliment Pharmacol Ther | Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. | 2021 | Details |
| A02377 | 34397849 | Medicine (Baltimore) | Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease. | 2021 | Details |
| A02380 | 34396890 | Arch Physiol Biochem | Hepatoprotection of capsaicin in alcoholic and non-alcoholic fatty liver diseases. | 2021 | Details |
| A02381 | 34396467 | Rev Endocr Metab Disord | Applications of artificial intelligence (AI) in researches on non-alcoholic fatty liver disease(NAFLD) : A systematic review. | 2021 | Details |
| A02382 | 34396022 | J Endocr Soc | Liver Fibrosis Indices for the Prediction of Mortality in Korean Subjects: A 16-Year Prospective Cohort Study. | 2021 | Details |
| A02391 | 34391652 | J Cardiothorac Vasc Anesth | Management of Patients With Non-alcoholic Steatohepatitis Undergoing Liver Transplantation: Considerations for the Anesthesiologist. | 2021 | Details |
| A02397 | 34387896 | Hepatology | Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin-like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice. | 2021 | Details |
| A02399 | 34386935 | Hepatol Int | First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. | 2021 | Details |
| A02401 | 34386600 | JGH Open | Prevalence of clinically relevant liver fibrosis due to nonalcoholic fatty liver disease in Indian individuals with type 2 diabetes. | 2021 | Details |
| A02406 | 34384565 | J Pharmacol Sci | Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice. | 2021 | Details |
| A02417 | 34381424 | Front Endocrinol (Lausanne) | Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population. | 2021 | Details |
| A02420 | 34380057 | J Hepatol | Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. | 2021 | Details |
| A02424 | 34375373 | J Gastrointestin Liver Dis | Liver-related Mortality is Increased in Lean Subjects with Non- alcoholic Fatty Liver Disease Compared to Overweight and Obese Subjects. | 2021 | Details |
| A02438 | 34371891 | Nutrients | Coffee Consumption and the Progression of NAFLD: A Systematic Review. | 2021 | Details |
| A02445 | 34369032 | J Biochem Mol Toxicol | Shc inhibitor idebenone ameliorates liver injury and fibrosis in dietary NASH in mice. | 2021 | Details |
| A02446 | 34368214 | Front Nutr | Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | 2021 | Details |
| A02448 | 34367500 | World J Hepatol | Prevalence and risk factors of steatosis and advanced fibrosis using transient elastography in the United States' adolescent population. | 2021 | Details |
| A02449 | 34367497 | World J Hepatol | Racial differences in prevalence and severity of non-alcoholic fatty liver disease. | 2021 | Details |
| A02461 | 34363981 | Diabetes Metab | Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. | 2021 | Details |
| A02468 | 34360999 | Int J Mol Sci | CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload. | 2021 | Details |
| A02469 | 34360923 | Int J Mol Sci | The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. | 2021 | Details |
| A02470 | 34360904 | Int J Mol Sci | Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA. | 2021 | Details |
| A02471 | 34360773 | Int J Mol Sci | Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics. | 2021 | Details |
| A02483 | 34358397 | Liver Int | Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus. | 2021 | Details |
| A02484 | 34358264 | PLoS One | Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression. | 2021 | Details |
| A02487 | 34356308 | Antioxidants (Basel) | Green Tea and Epigallocatechin Gallate (EGCG) for the Management of Nonalcoholic Fatty Liver Diseases (NAFLD): Insights into the Role of Oxidative Stress and Antioxidant Mechanism. | 2021 | Details |
| A02492 | 34354193 | Sci Rep | Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease. | 2021 | Details |
| A02494 | 34353365 | Clin Epigenetics | Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD. | 2021 | Details |
| A02499 | 34351306 | Horm Res Paediatr | Nonalcoholic Fatty Liver Disease in Children with Obesity: Narrative Review and Research Gaps. | 2021 | Details |
| A02504 | 34349535 | Diabetes Metab Syndr Obes | MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis. | 2021 | Details |
| A02507 | 34348281 | Dig Dis | ALT Levels in Treatment-Naive, Chronic Hepatitis B Patients with Concurrent Fatty Liver Disease: A US Nationwide Study. | 2021 | Details |
| A02510 | 34346799 | Expert Rev Mol Diagn | Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. | 2021 | Details |
| A02518 | 34343274 | Endocrinology | SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD. | 2021 | Details |
| A02522 | 34342164 | Physiol Rep | The effect of endurance training on non-alcoholic fatty liver disease in mice. | 2021 | Details |